Abstract: A process for forming a porous spherical silica material is provided. The process comprises mixing an alkali silicate with a mineral acid at pH and temperature sufficient to form a silica sol, mixing the silica sol with an oil and a surfactant to form a water-in-oil type emulsion, adding an alkaline solution to the emulsion to form a gel, adding a demulsifying agent and heating to a temperature of from about 60°° C. to about 90° C., and filtering, washing, optionally aging, and drying to obtain the porous spherical silica gel particles.

Abstract: Olefin catalyst systems comprising silica supports are provided. For example, in one embodiment, the olefin polymerization catalyst system comprises a silica support, a catalyst precursor compound, and an activator. The silica support comprises a plurality of silica gel particles. Each particle comprises a rigid network of amorphous silica. The particles are spherical, single gel particles that have an average aspect ratio of about 1.2 or less, an average pore volume of from about 1.4 ml/g to about 3 ml/g, an average surface area from about 200 m2/g to about 950 m2/g, and a median particle size from about 4 ?m to about 100 ?m.

Abstract: The present invention provides an African swine fever virus (ASFV) subunit vaccine which comprises: (i) one or more recombinant polynucleotides which encode polypeptides shown as SEQ ID NO: 1, 2 and 3 or an immunogenic fragment thereof; or a variant with at least 70% sequence identity to one of SEQ ID NO: 1, 2 or 3; wherein the total number of different ASFV polypeptides encoded by the one or more recombinant polynucleotides is 10 or fewer; or (ii) recombinant polypeptides shown as SEQ ID NO: 1, 2 and 3 or an immunogenic fragment thereof; or a variant with at least 70% sequence identity to one of SEQ ID NO: 1, 2 and 3; wherein vaccine comprises 10 or fewer different ASFV polypeptides.

Abstract: The present invention provides an attenuated African Swine Fever (ASF) virus which lacks a functional version of the following genes: multigene-family 360 genes 9L, 10L, 11L, 12L, 13L and 14L; and multigene-family 505 genes 1R, 2R, 3R and 4R. The invention further provides an attenuated African Swine Fever (ASF) virus which Lacks a functional version of the DP148R gene. The present invention also provides a vaccine comprising such an attenuated virus and its use to prevent ASF. Further, the invention relates to intranasal administration of an attenuated ASF virus.

Abstract: The present invention provides an attenuated African Swine Fever (ASF) virus which lacks a functional version of the following genes: multigene-family 360 genes 9L, 10L, 11L, 12L, 13L and 14L; and multigene-family 505 genes 1R, 2R, 3R and 4R. The invention further provides an attenuated African Swine Fever (ASF) virus which Lacks a functional version of the DP148R gene. The present invention also provides a vaccine comprising such an attenuated virus and its use to prevent ASF. Further, the invention relates to intranasal administration of an attenuated ASF virus.

Abstract: The present invention provides an attenuated African Swine Fever (ASF) virus which lacks a functional version of the following genes: multigene-family 360 genes 9L, 10L, 11L, 12L, 13L and 14L; and multigene-family 505 genes 1R, 2R, 3R and 4R. The invention further provides an attenuated African Swine Fever (ASF) virus which lacks a functional version of the DP148R gene. The present invention also provides a vaccine comprising such an attenuated virus and its use to prevent ASF. Further, the invention relates to intranasal administration of an attenuated ASF virus.

Abstract: The present invention provides an attenuated African Swine Fever (ASF) virus which lacks a functional version of the following genes: multigene-family 360 genes 9L, 10L, 11L, 12L, 13L and 14L; and multigene-family 505 genes 1R, 2R, 3R and 4R. The invention further provides an attenuated African Swine Fever (ASF) virus which lacks a functional version of the DP148R gene. The present invention also provides a vaccine comprising such an attenuated virus and its use to prevent ASF. Further, the invention relates to intranasal administration of an attenuated ASF virus.

Abstract: A timer circuit is disclosed. The timer, having a delay configured to track inversely with temperature of the memory device, includes a reference signal configured to increase in voltage, as the temperature of the memory device increases. The reference signal may be generated from a current that is derived from a bandgap reference circuit. The timer circuit includes a pull-down path made up of a plurality of selectable pull down transistors which are coupled to the reference signal at the gate. Resistance of the pull-down path is reduced as the reference signal is increased and the reduced resistance of the pull-down path decreases the delay of timer. A plurality of selectable delay elements may be preconfigured to adjust the delay and are coupled to the output path of the current starved inverter.

Abstract: A method and system for updating and maintaining cache coherency across nodes in a cluster. The method uses a combination of read and write locks on the instances of the cache, with some embodiments using a master locking database. Periodic validations of timestamps are used to identify lack of coherency of the cache, such as resulting from a network failure.

Abstract: A method of performing memory operations of a memory device having precharge, read and write states is disclosed. The method includes refreshing the memory device provided a refresh timer expired and the memory device is in the precharge state. The method further includes entering the precharge state, refreshing the memory device and returning to the read state provided the memory device is in the read state for a predetermined period of time. The memory device is refreshed provided the memory device is transitioning from the read state to the write state and the refresh timer has expired.

Abstract: A method and system for updating and maintaining cache coherency across nodes in a cluster. The method uses a combination of read and write locks on the instances of the cache, with some embodiments using a master locking database. Periodic validations of timestamps are used to identify lack of coherency of the cache, such as resulting from a network failure.